Latest Clinical Trials News

Argenica Therapeutics is gearing up for a pivotal late-stage clinical trial of its neuroprotective drug ARG-007 (xaranetide) in acute ischaemic stroke, backed by strong safety assays and solid funding.

Radiopharm Theranostics (ASX: RAD) has requested an immediate voluntary suspension of its shares pending a material capital raising announcement expected before markets open on 27 July 2026.

Atomo Diagnostics reported a 40% increase in FY26 revenue to $5.3 million, driven by a surge in HIV self-test sales and new OEM customer orders. The company is advancing its syphilis and liver test developments while enhancing manufacturing capacity.

Dimerix has strengthened its kidney disease pipeline with a US patent grant for DMX-652, extending protection until 2043 and setting the stage for a Phase 2 trial targeting acute kidney injury after cardiac surgery.

Cambium Bio has raised just over A$1 million through a strategic placement at a 17% premium, boosting a key shareholder’s stake as it advances its pivotal Phase 3 trial for dry eye disease.

Entropy Neurodynamics has reported breakthrough Phase 2 clinical results for its intravenous psilocin therapy in treatment-resistant Binge Eating Disorder, alongside strong Phase 2a data in Irritable Bowel Syndrome and a new US patent filing.

Noxopharm reported significant progress in its Sofra technology, highlighting enhanced cancer drug potential and preparations for a US FDA clinical trial, while managing tight cash reserves.

Optiscan Imaging has kicked off a US clinical trial with Mayo Clinic to test its InVue and InForm devices in breast conserving surgery, aiming to generate data for FDA 510(k) submissions and validate a new surgical-pathology workflow.

Radiopharm Theranostics reported robust Phase 2b results for RAD101 in brain metastases imaging, hitting 93% concordance with MRI and setting the stage for a U.S. Phase 3 trial. Meanwhile, its Phase 1 trial of RAD204 showed durable partial responses and good tolerability in advanced solid tumors.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its Phase 1b trial of PYC-003 for Polycystic Kidney Disease, alongside regulatory clearance for an Open-Label Extension allowing continuous dosing up to 24 months.

Paradigm Biopharmaceuticals has strengthened its balance sheet with a combined $5.75 million cash inflow from Australian Government R&D tax incentives, supporting its pivotal Phase 3 osteoarthritis trial and regulatory efforts.

Ceretas Limited is raising $8 million through an IPO to fund clinical trials and development of its novel therapeutic ultrasound device targeting Alzheimer’s disease symptoms.